



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/165,460	10/02/1998	JASPER D. RINE	B96-021-3	7914

23379 7590 02/21/2002

RICHARD ARON OSMAN
SCIENCE AND TECHNOLOGY LAW GROUP
75 DENISE DRIVE
HILLSBOROUGH, CA 94010

EXAMINER

RAMIREZ, DELIA M

ART UNIT	PAPER NUMBER
----------	--------------

1652

DATE MAILED: 02/21/2002

20

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No.

09/165,460

Applicant(s)

RINE ET AL.

Examiner

Delia M. Ramirez

Art Unit

1652

--Th MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 24 January 2002 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

PERIOD FOR REPLY [check either a) or b)]

- a) ☒ The period for reply expires 3 months from the mailing date of the final rejection.
- b) ☐ The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

1. ☐ A Notice of Appeal was filed on _____. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. ☐ The proposed amendment(s) will not be entered because:
- (a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);
 - (b) ☐ they raise the issue of new matter (see Note below);
 - (c) ☐ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
 - (d) ☐ they present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: _____

3. ☐ Applicant's reply has overcome the following rejection(s): _____.
4. ☐ Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☒ request for reconsideration has been considered but does NOT place the application in condition for allowance because: see attachment.
6. ☐ The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7. ☒ For purposes of Appeal, the proposed amendment(s) a) ☐ will not be entered or b) ☒ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: none.

Claim(s) objected to: _____.

Claim(s) rejected: 31, 33-35, 37-39, 41-43, 45-46.

Claim(s) withdrawn from consideration: _____.

8. ☐ The proposed drawing correction filed on _____ is a) ☐ approved or b) ☐ disapproved by the Examiner.
9. ☐ Note the attached Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____.
10. ☒ Other: see attached references

ADVISORY ACTION

1. Claims 31, 33-35, 37-39, 41-43, and 45-46 are pending in the application.
2. Applicants allege in the amendment filed in Paper No. 19, filed 1/24/2002, that the 103(a) rejection applied to claims 31, 33-34 and 41-42 over Rose et al. (GenBank accession number Z49617) in view of Nozaki et al. (US Patent No. 4,997,767) and the 103(a) rejection applied to claims 35, 37-38, 43, 45-46 over Lye et al. (GenBank accession number Z49260) are not in compliance with the notice requirement of 35 U.S.C. 132. According to the records of the instant application, two Notices of References Cited (PTO-892) have been sent to Applicant in Paper No. 11, mailed on 9/13/2000, and in Paper No. 16, mailed 3/27/2001, indicating that the cited references were sent to Applicant by the previous Examiner of record. Also, according to the records of the instant application, the reasons for applying said rejections have been extensively discussed in the previous Office Actions. In any event, copies of the Rose et al. and Lye et al. references (alignments) are being forwarded to Applicants with this action.
3. Applicants argue that the creation dates relied on by the Examiner to determine the public availability of Rose et al. (GenBank accession number Z49617, October 6, 1995) and Lye et al. (GenBank accession number Z49260, May 16, 1995) are not the dates when such references were available to the public. After communications with representatives of GenBank and EMBL, which is the database where these sequences were originally filed, it was indicated that the creation dates are the dates when these entries first become available to the public. According to their records, the creation dates for entries Z49617 and Z49260 are October 6, 1995 and May 16, 1995. Therefore, these references are considered valid prior art over Applicant's earliest priority date of August 7, 1996.

Art Unit: 1652

4. In regard to the 103(a) rejection of claims 31, 33-34, and 39, 41-42, which is discussed in previous Office Actions, Applicants argue that while the entire yeast genome had been largely sequenced at the time the invention was made and open reading frames were identified, the claimed compositions would be neither anticipated nor obvious. Applicants further argue that the instant invention requires the coding sequence to be operatively joined to a promoter and that there was no motivation to select an open reading frame of unknown function, link it to an operative promoter, and express it in a vector. These arguments have been fully considered but are not found persuasive because once an open reading frame is known, one of ordinary skill in the art is motivated to insert the open reading frame in a vector with an operably linked promoter in order to characterize the protein encoded by such open reading frame. The existence of many open reading frames of unknown function does not eliminate the motivation to insert the open reading frame sequence into a vector to characterize the protein. On the contrary, one of skill in the art is highly motivated to determine the function of proteins encoded by unknown open reading frames.

5. In regard to the 103(a) rejection of claims 35, 37-38 and 43, 45-46, which is discussed in previous Office Actions, Applicants argue that Lye discloses computer predictions of thousands of possible coding sequences and does not disclose any gene or gene product. Applicants also argue that the Examiner uses Applicant's own disclosure to select one of many *Saccharomyces* genes and to provide motivation to recombine it in an expression vector. Furthermore, Applicants argue that in the absence of any evidence for function, there would be no motivation to select out one of the thousands of yeast ORFs of unknown function. These arguments have been fully considered but are not found persuasive because once an open reading frame is known

Art Unit: 1652

or even predicted, one of ordinary skill in the art is motivated to insert the open reading frame in a vector with an operably linked promoter in order to characterize the protein encoded by such open reading frame. The existence of many open reading frames of unknown function does not eliminate the motivation to insert the open reading frame sequence into a vector to characterize the protein. On the contrary, one of skill in the art is highly motivated to determine the function of proteins encoded by unknown open reading frames. Constructing a vector comprising the polynucleotide of SEQ ID NO: 3 or a vector comprising a polynucleotide which will hybridize under stringent conditions to SEQ ID NO: 3, and transforming a host cell to express the corresponding protein would have been obvious to one of skill in the art at the time the invention was made once it was known that said sequence was an open reading frame. In response to Applicant's argument that the Examiner's conclusion of obviousness is based upon Applicant's disclosure, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the invention was made, and does not include knowledge gleaned only from Applicant's disclosure, such reconstruction is proper. See *In re McLaughlin*, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). Moreover, the motivation disclosed in Applicant's disclosure is not the same motivation provided by the Examiner.

6. The request for consideration is acknowledged. The amendment filed on 1/24/2002 under 37 CFR 1.116 in reply to the final rejection has been considered but is not deemed to place the application in condition for allowance. For Appeal purposes, the status of the pending claims is as follows:

Art Unit: 1652

Claims allowed: NONE

Claims rejected: 31, 33-35, 37-39, 41-43, 45-46

Claims objected: NONE

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Delia M. Ramirez whose telephone number is (703) 306-0288.

The examiner can normally be reached on Monday-Friday from 8:30 AM to 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Ponnathapura Achutamurthy can be reached on (703) 308-3804. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

DR
February 15, 2002

Delia M. Ramirez, Ph.D.
Patent Examiner
Art Unit 1652



PONNATHAPU ACHUTAMURTHY
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 12, 2002, 13:20:11 ; Search time 4622.84 Seconds
(without alignments)
10520.305 Million cell updates/sec

Title: US-09-165-460A-3

Perfect score: 2948

Sequence: 1 tgaactgttgatgaacaaag.....ggggaggataagaatcaca 2948

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 1472140 seqs, 824859755 residues

Total number of hits satisfying chosen parameters: 2944280

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl:*

- 1: gb_ba:*
- 2: gb_htg:*
- 3: gb_in:*
- 4: gb_om:*
- 5: gb_ov:*
- 6: gb_pat:*
- 7: gb_ph:*
- 8: gb_pl:*
- 9: gb_pr:*
- 10: gb_ro:*
- 11: gb_sts:*
- 12: gb_sy:*
- 13: gb_un:*
- 14: gb_vl:*
- 15: em_ba:*
- 16: em_fun:*
- 17: em_hum:*
- 18: em_in:*
- 19: em_om:*
- 20: em_or:*
- 21: em_ov:*
- 22: em_pat:*
- 23: em_ph:*
- 24: em_pl:*
- 25: em_ro:*
- 26: em_sts:*
- 27: em_sy:*
- 28: em_un:*
- 29: em_vi:*
- 30: em_htgo_hum:*
- 31: em_htgo_inv:*
- 32: em_htgo_rod:*
- 33: em_htg_hum:*
- 34: em_htg_inv:*
- 35: em_htg_rod:*
- 36: em_htg_other:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

8

Result No.	Score	Query Match	Length	DB ID	Description
C 1	2948	100.0	29987	8	SC8156
2	1560.4	52.9	4156	8	D50276
3	1361	46.2	4130	8	YSNCNR1G
4	1163	39.5	4225	8	SCU65682
5	1069.4	36.3	3250	8	SCU32580
6	931	31.6	3525	8	SCU63849
7	786.8	26.7	3240	8	YSCBUL1
8	703.8	23.9	3020	8	SCRDSIGEN
9	225.2	7.6	270	8	YSCGEN58X
10	143.8	4.9	27559	8	SC83339
11	75	2.5	2023	8	SC1NR068C
12	71.8	2.4	4775	8	SCU32938
13	68	2.3	780	11	CNS06K8B
14	65.6	2.2	256172	2	AC005139
15	65.6	2.2	310779	2	AC005140
16	64.4	2.2	904	11	CNS06I89
17	64.4	2.2	86827	3	PFMAL3P5
18	63.4	2.2	1920	3	PFGTUB
19	63.4	2.2	110000	2	PFMAL13P2_0
20	62	2.1	253305	3	PFMAL3P7
21	61.6	2.1	1141	6	AX083744
22	60.8	2.1	234112	3	PFMAL4P2
23	60.6	2.1	202872	2	AC016160
24	60	2.0	5632	3	AF310892
25	59.4	2.0	3214	3	AF019980
26	59.4	2.0	318221	2	PFMAL13P3
27	58.8	2.0	321003	2	PFMAL4P3
28	58.4	2.0	78439	17	HS085197
29	58.4	2.0	169546	2	AC004157
30	58.4	2.0	245802	2	AC006279
31	58.4	2.0	251124	9	HUAE000660
32	58.2	2.0	153098	3	PFMAL3P2
33	58	2.0	169794	2	AC004688
34	58	2.0	178137	9	AC011302
35	57.8	2.0	13684	3	AE001403
36	57.8	2.0	153477	2	AC006278
37	57.6	2.0	53932	2	AC023371
38	57	1.9	12029	3	AE001431
39	57	1.9	163443	2	AC006280
40	57	1.9	178273	2	AC005308
41	57	1.9	196149	2	AC004709
42	56.8	1.9	67970	3	PFMAL1P3
43	56.8	1.9	149627	9	AC087428
44	56.6	1.9	92633	2	PFMAL4P1_3
45	56.6	1.9	153477	2	AC006278

ALIGNMENTS

RESULT 1
LOCUS SC8156/c
DEFINITION S.cerevisiae chromosome XIII cosmid 8156.
ACCESSION Z49260 Z71257
VERSION Z49260.1 GI:809081
KEYWORDS BUL1; cytochrome b5; DAG1; initiation factor 1A; inorganic pyrophosphatase; IPP2; nitrate reductase; orotate phosphoribosyltransferase; tau element; TIF11; TP53; transfer RNA-Gln; trehalose-phosphate synthase; U6 snRNP; URAL0.
SOURCE baker's yeast.
ORGANISM Saccharomyces cerevisiae
Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes; Saccharomycetales; Saccharomycetaceae; Saccharomyces.
REFERENCE 1 (bases 1 to 29987)
AUTHORS Lye, G. and Churcher, C.M.
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 29987)
AUTHORS Barrell, B. and Rajandream, M.A.
TITLE Direct Submission

SC8156 29987 bp DNA PLN 11-AUG-1997
S.cerevisiae chromosome XIII cosmid 8156.

JOURNAL

Submitted (12-MAY-1995) Saccharomyces cerevisiae chromosome XIII
sequencing project, Sanger Centre, Hinxton Hall, Hinxton, Cambridge
CB10 1RQ E-mail: barriellesanger.ac.uk

COMMENT

Notes:
All CDS over 100 codons have been analysed. CDS that are completely
overlapped and those that are overlapped by more than 50%
of their length by a larger CDS have been omitted from this
analysis.
Details of the omitted CDS are available on request. The more
significant matches with motifs in the PROSITE database are
also included but some of these may be fortuitous. The length in
codons and the calculated codon adaptation index (CAI)
is given for each CDS.
Cosmid 8156 is overlapped at the start by cosmid 9920, embl entry
SC9920,

FEATURES

source

accession no. 248639 and at the end by cosmid 8021.

Location/Qualifiers

1. 29987
/organism="Saccharomyces cerevisiae"
/strain="AB972"
/db_xref="taxon:4932"
/chromosome="XIII"
/clone="cosmid 8156"
/map="13R"

CDS

complement(<1..356)
/note="YM8156.01c, unknown, len: 118, CAI: 0.14, overlaps
and extends YM9920.13c"
/codon_start=1
/product="unknown"
/protein_id="CAA89242.1"
/db_xref="GI:809082"
/db_xref="SWISS-PROT:O03496"
/translation="MTDVFSSQIEFLRVKEFLIANNPAKINNENKDAVLTQIEHD
FRYLQYKDGLPNLESRLFPDTSICLLRSQIIASKIDSQEFLSAVKEQLLT
ENANIIIEYVLDFA"
1..140

misc_feature

/note="overlap with SC9920.248639 S. cerevisiae chromosome
XIII cosmid 9920"
complement(851..1312)
/gene="TIF1"
complement(851..1312)
/gene="TIF1"
/note="YM8156.02c TIF1 gene, IF1A_YEAST, P3891,
initiation factor 1a"
/codon_start=1
/product="tif1p"
/protein_id="CAA89243.1"
/db_xref="GI:809083"
/db_xref="SWISS-PROT:P38912"
/translation="MGKNTKGGKGRGKNDSDGPKRELIYKEGQGYAQITKMLGN
GRVASCFDGNKMAHTRGLRKKYVMQGDIIILSLRDFDQDCDYVHKYNLDEART
LKNQGLPENAKINETNFGFSEDEYNFFEGNADEDEGEDELDIDDI"
complement(1678..4842)
/gene="TPS3"
complement(1678..4842)
/gene="TPS3"

gene

CDS

/note="YM8156.03c, TPS3 gene, len: 1054, CAI: 0.21,
SW.TPS3_YEAST P38426, alpha,alpha-trehalose-phosphate
synthase and PIR:S27471; PS00213 Lipocalin signature;
translation in TPS3_YEAST starts at amino acid 33 in this
sequence"
/codon_start=1
/product="tps3p"
/protein_id="CAA89244.1"
/db_xref="GI:809084"
/db_xref="SWISS-PROT:P38426"
/translation="MTIIIVASLFLPTQPEADVTNSDAKLIVESMIKVDONQELS
NNKQSSSVTSASHYIGLPQEAQINGEPLQRAVNGSPATGVNHNEMKLSQQFL
EILTANATAANGSIPRANPVSSGAQRPVEFFSAPSARVSCPOEASASSILA
SSSAHNDLSSLMKNPLNLSFDSPHVRSSKSAVITPVSKSPDVPDPAVDYAVK
REEQOQASLPKMKRVSGTAGDSSTASSSSNLRYSQODNFIEDTSEDSDSLE
TDATKYNVPKFGGYSNAKLASLRMSYELFKHLPTIYDSDKNGSLKNAVNIAY
AEKTVKPVSWGTNGITDELPHVEVCHIKSKLEQDFSSFPVVTDDITFKGAKNYA

OM

misc_feature

/gene="TPS3"
complement(2260..2301)

CDS

/note="PS00213 Lipocalin signature"
5199..6140
/note="YM8156.04, unknown, len: 313, CAI: 0.11, previous
noted ORF, SW:YTP3_YEAST P38430"
/codon_start=1
/product="unknown"
/protein_id="CAA89245.1"
/db_xref="GI:809085"
/db_xref="SWISS-PROT:P38430"
/translation="MNLVDACHVITPDNTFCGDDGSGQTLRCVMSNPTDNN
KLAGRSKNDICVGFVHPYSHLFVGSRRKVSHTQVLEYNEQFDSLVQ
PEPDLSEYIKRENDTIVSVEIGELDKLRLPANGFTMQNEKARLTATVVKLSH
TVFRFLARHTSKPISHDVKGKLDICNEELLATYHSVKICLHSTVGSKEULI
QMLKKFPDRIFVLSKWINFQDEEGDALVSLPSTCILTETDYPIDNPDFSYQK
TEQLQYNAQIARAWDETLDASQAALRVYENQFKF"
6392..6997

CDS

/note="YM8156.05, unknown, len: 301, CAI: 0.12,
SW:YTP2_YEAST P38429 previously noted ORF"
/codon_start=1
/product="unknown"
/protein_id="CAA89246.1"
/db_xref="GI:809086"
/db_xref="SWISS-PROT:P38429"
/translation="MARPVNTAETSGRPTGGGYASNNNGSNNNGSNNNNNN
NNNNNNNNNGPTSGRTNGKRLTAQOQYIKNLIEHTITDNRDPLRPSHP
DFEYTDALRYKDHQFDLPDNLTLQGLSLGKAKTYSYKRNTOGQHDKRIH
DLANVRRHDEHSIKETDCIPQFIYKVKQKKKKEFRG"
7278..7889

CDS

/note="YM8156.06, unknown, len: 301, CAI: 0.13,
SW:YTP1_YEAST P38428, extends previously noted ORF"
/codon_start=1
/product="unknown"
/protein_id="CAA89247.1"
/db_xref="GI:809087"
/db_xref="SWISS-PROT:P38428"
/translation="MEDSRLITLILVFGVIFLKFFQSNQHPSAORLSAT. AG;
PGSTONALRRTRGVNGHPTVQVETVONLAPNLHPQIYRISLENTGSVEIYVER
LRGDEFSEPPGPRAPMAGNAVDNNAAGGGEFNDPKKMICAEMLDKFHDVL
EDMSNLSFKDIDIERKLLVQAKNLETKLQSDKDLQSLT"
complement(8013..9398)

CDS

/note="YM8156.07c, unknown, len: 461, CAI: 0.11"
/codon_start=1
/product="unknown"
/protein_id="CAA89248.1"
/db_xref="GI:809088"
/db_xref="SWISS-PROT:Q03508"
/translation="MEEFEFRKMGSSRCGNHRLVRKNWSCACELAVPFEVPEHAI
TKLHIYDNTLFTATPGTEQLYTRELLNLTSSLPNGMWRNPGFLQAALEISKT
PRYSWNADIVKLAESYSADTISVLNLTGSESEFKLIEHALATQSRHWCSENEF
RFNAVCLAKRAISSETSKYKELMDEFLYPSLRELSIYDDRIIDAFKSFHSLD
LPRLKWSAIPVPTKSPRQELMWDVMDKNNNSQALSTQKDFLRRTPQIGIL
CTASHRLSIVIKLRKRRRTFKLIEHLYIPCAEPKDIAPALEIAKAVSWND
TRITDSEKVOHISQIFLEQPGKIVFQVTLAVIASAHNRKRLVYVFKATPEI
NRYTFKPEIYVTHGFYKEDIEDLEVYTERLINCKEDIEHWVPLDITIPKAFGR
AKLAAPCSNA"
9991..12852
/note="YM8156.08, unknown, len: 953, CAI: 0.20, probable
integral membrane glycoprotein"
/codon_start=1


```

/product="unknown"
/protein_id="CA89249.1"
/db_xref="GI:809089"
/db_xref="SWISS-PROT:Q03516"
/translation="MNSTNSTSTATSTNTSTOQVTVSLVSGTIFGVFVIAFLIL
RIKLRIYEPKSSFNLINEKKPPLPOGVNQLKPKKSDNFVIOQGLDGFIFLR
YFLIIAYICAVMSYIPIILLISNAGNHEGLNQLAYQNVKRGYFAHFCGWIF
FWGLYIIYRLIYPTSMKQAVLASPRYAKLSRNLVFOYKPYLSEEFSLKDFG
VKRYIAGSGSIEAMVKARDMAIQLEGAETKYKALKIKLNKSPOLSYSDNI
AEYVPDKRPHHKINKVAKFFKQVDTISYIKELPKLNOKVLALEDHNSPPNS
VFVEFQYQAAQAQITTYHAPLPMTPYIGIEPDDVWVFNLMFWERLGRVSAV
SIALVALVILWAFVAVGMISNITSLNEVWELFIYKLPKOLLGLTSLAPTVALAV
LMSPLPKFIRGMATOCQASQNVETFOQAFVAFVIOVELVTLSSAATSTVEIV
KEPKAMDLLASNLPRKASNFMSVILQSLSSGALLQIVPLILFYGLAFLDGTVR
KKNRFGSLSGMONGTAPFVNTNIAVITSYSIIISPLILFAVAFVILYIAYLNLT
XYVQESDGMGIYPRALFOTIVGIYIQICLLGLFAVGKMGPIVLQVIGICVTVLI
HLHLSAADFHLKSVIPDVTMKPLDGVSDTPSFKNYKGIESTKYKNTFGANIMDGI
KELPEFPIKKYHKRESVETQOVENSISENTPEYQPNPANEADGHNAENLIED
VPLLADGTWKIPAPWKREFLPHIYIYKAVKSRLEPIYGLVDPDEREDISHA
YDYPVARSQCPDELWIPRDPFGSKLLISDVGVMNDENATIDENLKFTRDVPY
NDVDEANGANGEFDTASKENNPFPADPKYKEERSAV"
/gene="14177"
/cds="14177"
/gene="IPP2"
/gene="IPP2"
/gene="IPP2"
/feature="note"
/note="Y08156.09, IPP2 gene (PPA2), len: 310, CAI: 0.14,
SW:IPY2_YEAST, P28239, inorganic pyrophosphatase,
mitochondrial; contains PS00387 inorganic pyrophosphatase
signature"
/codon_start=1
/product="ipp2p"
/protein_id="CA89250.1"
/db_xref="GI:809090"
/db_xref="SWISS-PROT:P28239"
/translation="MNLRLNALTSKARSIERLKKQILNLSIRNRQFSTIQGSKYT
LGFKKYLTLLNGEVGFHFDVPLDLNEHEKTYNIVEIPRWTTGKFEISKELRFDIV

```

Query Match

```

Best Local Similarity 100.0%; Score 2948; DB 8; Length 2998;
Matches 2948; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 tgaactgtgatgaacaaagagagctgacaaagcttgcacgatttgcacgatttccca 60
DB 27785 TGAACGTGTGATGAATGAACACCAAGCTGACAAAGCATCAAAAGCTTGTACGATGATTCCA 27726

QY 61 ttcaaaatttggtaatatgaacaaagttcaacaaagattttcttgaattaaatgatt 120
DB 27725 TTCAAAATTTGTGAATGAACACCAAGTTCAACAGAAATTTCTTGAATTAATGAGTT 27666

QY 121 atataatgaatagggagacgctaggccaaaggaactgaaatttacagattttattac 180
DB 27665 ATATAATATGAATAGGGAGACCGTAGGCCAAAGGAACTGAAATTTACAGATTTTATTAC 27606

QY 181 ttccacagctgttaacagatgaaagacatttgcaacttgaaagtttagttgcacaaatt 240
DB 27605 TTCACAGCTGTTTACAGATATCGAAAGCAATTTGCAACTTTGAAAGTTAGTGTTCACAACT 27546

QY 241 atccacacatttttaaaaaacaggctcagttacccttaaacacacactcaaacgacgattatc 300
DB 27545 ATCCACACATTTTAAAAACAGGTGAGTACCTTAACACACACTCAACACGCGCATATC 27486

QY 301 tgaggattcaatcgcacacaggttaacggttagtttcacgtgcgcagttcagcgttcatt 360
DB 27485 TGAGGATTCAATATCGCACACAGGTAAACGGTAGTTTCATCGTCCCGCAGTTACGGTCATT 27426

QY 361 aacgcagcttaactttccaaagagtagttatttttaccatagcggtagctgcgtctac 420
DB 27425 AACGCCAGTAACCTTCTTCCATCCAAAGAGTAGTTTATTTTACCCTAGCGGTAGCTCGTCTAC 27366

QY 421 ttccctgaaattacagaccagattgttcataaaatgggttagattgtcctcttcacagta 480
DB 27365 TTCCCTGAAATTTACAGACCAGATTGTTTCATATAATGGGTGTAGGATTGCTCTTTACAGTA 27306

```

```

QY 481 caaacgacacattaatgtgaacttggaatttaataagggacattaaaggaacacttaattcc 540
DB 27305 CAACGACACATTAATGTGAACCTTGAATTTAATAGGCAATTAAGGAACCTTAATTC 27246

QY 541 aagttttgaaagctgcctatgttgtaggtgtttattcgctgcgtcagtaagattcaatttga 600
DB 27245 AAGTTTGAAGCTGCCTATGTGTAGGTTTATTGTCGCTTCAGTAAGATTAAATTTGA 27186

QY 601 aaacattcttggtgtagcgaagattgatccctatttctgttagcgaagtgcacaaaaa 660
DB 27185 AAACCATCTTGGCTAGCGAAGATTGATATCCCTATTCTGTAGGCAAGTGACAAAATA 27126

QY 661 aaaaaacattagaaaaatttcgttactttcttatagatatagatatagttatggttt 720
DB 27125 AAAAAACATTAGAAAAATTCGTACTTCTTCTATATAGATATAGATATATGATGTTT 27066

QY 721 gcttatagatgaaggtatttatcgctcctcttgcattccctatttccctatttataataaattcttt 780
DB 27065 GCTTATAGATGAAGGTATTATCCGGCTTGTATCCCTATTATTAATAAATTCCTTT 27006

QY 781 taaaatgcattttctggtgcctctttgtgctctctgtattttttttttttttttttttttggaccactg 84
DB 27005 TAAATGCATTTCTGCTGCTCTTTGCTGCTGATATTTTCTTTTGGACCACCTG 26946

QY 841 gatggaaaacatttgatgatttattacccttatttcaagttaactaaatcagatttt 900
DB 26945 GATGGAAAACCTTTGATGATTTATTACCTTTATTTAAATTTACTAAATATCAGATT 26886

QY 901 caggaaacaaacataagattttcttgcagaaaaataanaacgaaataaattgatgctt 960
DB 26885 CAGGAACAAAACATAGAAATTTCTTGTCAAGAAAAATAAAGCAATAAATGATGCTT 26826

QY 961 tgactactgactctgtctatagagagaacacagacgaactcactcaacttctcaactt 1020
DB 26825 TGACTACTGACTCTGTCTATAGAGAACACAGACAGCATGCTCAATTTCTCAACATT 26766

QY 1021 tctagtgctctatacatctccatctctatgtgctaccgctatatgcaacttcacacac 1080
DB 26765 TCTAGTGCTCTATATATCTCCATATCTTATGCTACCTGCTATATGCAACTTACAACT 26706

QY 1081 agaaaggtctaaacagagataactcctcgaacgattaaactcgaatcgaacaaacttaacat 1140
DB 26705 AGAAGGCTTAACAGAGATAACTCCTCGAACGATTAATTCGATCGCAAAACCTTCAAT 26646

QY 1141 tatgctaatttccaaacttttttggggtgcttttttcaactcactcacttacttagtaccac 1200
DB 26645 TATGCTAATTTCCAACTTTTGTGCTGCTTTTTCATCAATCTCAATATCTAGTACCAC 26586

QY 1201 ttacacataaagtttcaagagacgacttttaggttaggtattatcccgaggttattacgc 1260
DB 26585 TTACACATAAAGTTTCAAGGACGCAATTTTAGGCTTAGGTATTATCCAGGTTTATACGC 26526

QY 1261 tgcattgccaacaccttggcaattcagccagttcgtggaagacttaacgaaatggttgc 1320
DB 26525 TGCATTGCCAAACCTTGGCAATTCAGCCGCTCGTGAAGAACTTAAACGAAATGCTGTC 26466

QY 1321 gacgttatgaccttatatttgggacccggttttagattttttattatattattattataa 1380
DB 26465 GATGTTATTGACCTTATATTGGACCCGTTTATAGATTTTATATATATCATTTATAA 26406

QY 1381 tccaaagagctctataactgaagatttttaccatgaattcctgaattttgaggttcag 1440
DB 26405 TCCAAAGAGCTCTATACATTGAAGATTTTACCATGAATTCCTGAATATTGAGGTTTCAG 26346

QY 1441 gaattttattttgaccacaaactgaaggaataattttacacgctcaaatgcttttgactac 1500
DB 26345 GAATTTTATATTGGACCAATAACTGAGGAATAATTTTACAGGTCAATGCTTTTGACTAC 26286

QY 1501 gtacttaaaccttaacccgattcgcacactgaactgaactcaacagtttattttggcaaccatc 1560
DB 26285 GTACTTAAACCTTAACCGCATTCGCAACTAAGCTATCAACAGTATTTTGGCAACCACTC 26226

QY 1561 gcttttttttggacttgcgcacacaccactgatttatgaggaattacaggaaggtccat 1620

```


SUMMARIES

ALIGNMENTS

JOURNAL

Submitted (25-SEP-1995) Data collected by MIPS on behalf of the European yeast chromosome X sequencing project. MIPS at the Max-Planck-Institut fuer Biochemie, Am Klopferspitz 18a D-82152

QY	331	aggccttattcatgtttgatcttagacgagattctcgaccattcctcaaatcctcaatcctcgctggaaa	390
DB	61	aggcctttattcatgtttgatcttagacgagattctcgaccattcctcaaatcctcaatcctcgctggaaa	120
QY	391	ttaatcattttcgggtttctcgatgigcccaattttcttggaattcttacttgacgtacagaa	450
DB	121	ttaatcattttcgggtttctcgatgigcccaattttcttggaattcttacttgacgtacagaa	180
QY	451	cagtaccagaaagctatctgaacacaaagtttgcacactgtctcggaaagacgaattgatgat	510
DB	181	cagtaccagaaagctatctgaacacaaagtttgcacactgtctcggaaagacgaattgatgat	240
QY	511	gaacttttataaatacaaggaaactactcccggggccaaaggccaaagttctccattttcggt	570
DB	241	gaacttttataaatacaaggaaactactcccggggccaaaggccaaagttctccattttcggt	300
QY	571	gagctotataaacctagcccaaaagctagttttctcaaatnccgacctcttcccataaatc	630
DB	301	gagctotataaacctagcccaaaagctagttttctcaaatnccgacctcttcccataaatc	360
QY	631	tggcacaatggccgtttctttattgaatgcagtcctcgcgcagtcagatttcaatgatgtctcc	690
DB	361	tggcacaatggccgtttctttattgaatgcagtcctcgcgcagtcagatttcaatgatgtctcc	420
QY	691	actgtcgacagagatttatgcttcttgggtctcttaccagtttcttaccatttctcacttggttgat	750
DB	421	actgtcgacagagatttatgcttcttgggtctcttaccagtttcttaccatttctcacttggttgat	480
QY	751	ttgccactcttactatagccatttttctcgtggaaagaaaaatttggtttccaaataaatg	810
DB	481	ttgccactcttactatagccatttttctcgtggaaagaaaaatttggtttccaaataaatg	540
QY	811	accgtccaactatgatcacccgatgatcaagagctgcactttggcgatgatgtattggt	870
DB	541	accgtccaactatgatcacccgatgatcaagagctgcactttggcgatgatgtattggt	600
QY	871	ggcccaactcttactgttcttcttaagatctttgataaattcccactgatttccctttgg	930
DB	601	ggcccaactcttactgttcttcttaagatctttgataaattcccactgatttccctttgg	660
QY	931	tacattatggtcttcttcttgcgttgcacaaatttagccatgacaaatccactcagctcttc	990
DB	661	tacattatggtcttcttcttgcgttgcacaaatttagccatgacaaatccactcagctcttc	720
QY	991	atcattgccaagttaataaagtttcaactccatttggaggacggtgaaactgaaaaaatctatt	1050
DB	721	atcattgccaagttaataaagtttcaactccatttggaggacggtgaaactgaaaaaatctatt	780
QY	1051	gaaagtgtggccgatagagttgggttcccctctctagataagaatttttgoattgacggctca	1110
DB	781	gaaagtgtggccgatagagttgggttcccctctctagataagaatttttgoattgacggctca	840
QY	1111	aaaagatctctctatccaacgcgatatttccagaggtttgccattccactcccaagaagaatt	1170
DB	841	aaaagatctctctatccaacgcgatatttccagaggtttgccattccactcccaagaagaatt	900
QY	1171	gttttgttcgacactttagtgaacagtaattctactgataagatttaccggctgttttgccc	1230
DB	901	gttttgttcgacactttagtgaacagtaattctactgataagatttaccggctgttttgccc	960
QY	1231	catgaatcgggtcactgcgcaaaaaaacacacatcgtttaatatggtcatcttttagtcaattg	1290
DB	961	catgaatcgggtcactgcgcaaaaaaacacacatcgtttaatatggtcatcttttagtcaattg	1020
QY	1291	cacacctctctcatctttctcccttttcacagcatctcagagaatacatcattttacaac	1350
DB	1021	cacacctctctcatctttctcccttttcacagcatctcagagaatacatcattttacaac	1080
QY	1351	accttggcgtttttcttagaagtcacctggcgagttttgttgatcccggtttatcactaag	1410
DB	1081	accttggcgtttttcttagaagtcacctggcgagttttgttgatcccggtttatcactaag	1140
QY	1411	gaattcccaattatcattggatttatgtatttaacgaccttatcaactccactcgaaagt	1470